Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1121-1130 of 1,281) with videos related to

Pageof 129
Sort By:
Obesity Research & Clinical Practice|May 24, 2021
Metabolic syndrome screening using visceral adipose tissue (VAT) from opportunistic MRI locations in a multi-ethnic populationRosa C Villegas-Valle, Unhee Lim, Gertraud Maskarinec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Konstantin Laktionov, Sang-We Kim, et al.
Endocrinology|July 9, 2005
A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulationAndrew G Geiser, Conrad W Hummel, Michael W Draper, et al.
JTO Clinical and Research Reports|September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential TherapiesSally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Nature Communications|November 29, 2014
Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impactLei Li, Yuhong Wei, Christine To, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials GroupCesare Gridelli, Ciro Gallo, Frances A Shepherd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcomeMing-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 19, 2025
Bovine Endometrium Drives and Responds to Divergence of In Vitro Produced Conceptus BiochemistryKatheryn D Peterson, Mary A Oliver, Trevor F Freeman, et al.
Pageof 129

Showing results (1121-1130 of 1,281) with videos related to

Sort By:
Pageof 129
Obesity Research & Clinical Practice|May 24, 2021
Metabolic syndrome screening using visceral adipose tissue (VAT) from opportunistic MRI locations in a multi-ethnic populationRosa C Villegas-Valle, Unhee Lim, Gertraud Maskarinec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Konstantin Laktionov, Sang-We Kim, et al.
Endocrinology|July 9, 2005
A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulationAndrew G Geiser, Conrad W Hummel, Michael W Draper, et al.
JTO Clinical and Research Reports|September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential TherapiesSally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Nature Communications|November 29, 2014
Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impactLei Li, Yuhong Wei, Christine To, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials GroupCesare Gridelli, Ciro Gallo, Frances A Shepherd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcomeMing-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 19, 2025
Bovine Endometrium Drives and Responds to Divergence of In Vitro Produced Conceptus BiochemistryKatheryn D Peterson, Mary A Oliver, Trevor F Freeman, et al.
Pageof 129